DGIdb - RASBURICASE Drug Record

RASBURICASE chembl:CHEMBL1201594 Approved

Alternate Names:

URATE OXIDASE
SR-29142
RASBURICASE
ELITEK
FASTURTEC
URICASE
rxcui:283821
drugbank:00049
chembl:CHEMBL1201594
chemidplus:134774-45-1

Drug Info:

(0 More Sources)

Publications:

Pui CH et al., 1997, Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies., Leukemia
Akande M et al., 2017, Rasburicase-induced Hemolytic Anemia in an Adolescent With Unknown Glucose-6-Phosphate Dehydrogenase Deficiency., J Pediatr Pharmacol Ther
Cooling L, 2017, Brisk clinical response to erythrocytapheresis in a G6PD-deficient patient with rasburicase-induced methemoglobinemia., J Clin Apher
Montgomery KW et al., 2017, A perfect storm: Tumor lysis syndrome with rasburicase-induced methemoglobinemia in a G6PD deficient adult., J Clin Apher
Oluwasanjo A et al., 2015, Rasburicase-induced methaemoglobinaemia and G6PD deficiency in an unusual suspect., Br J Haematol
Zhang B et al., 2014, Tumor lysis syndrome and acute anemia in an African-American man with chronic lymphocytic leukemia., Oxf Med Case Reports
Bontant T et al., 2014, Methaemoglobinaemia in a G6PD-deficient child treated with rasburicase., BMJ Case Rep
McDonagh EM et al., 2014, PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics., Pharmacogenet Genomics
Relling MV et al., 2014, Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype., Clin Pharmacol Ther
Roberts DA et al., 2015, Rasburicase-induced methemoglobinemia in two African-American female patients: an under-recognized and continued problem., Eur J Haematol
Luzzatto L et al., 2014, G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications., Br J Haematol
Pansy J et al., 2014, Cyanosis in a male Nigerian infant with acute kidney injury: answers., Pediatr Nephrol
Cheah CY et al., 2013, Rasburicase causing severe oxidative hemolysis and methemoglobinemia in a patient with previously unrecognized glucose-6-phosphate dehydrogenase deficiency., Acta Haematol
Zaramella P et al., 2013, Lethal effect of a single dose of rasburicase in a preterm newborn infant., Pediatrics
Sonbol MB et al., 2013, Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase., Am J Hematol
Ng JS et al., 2012, Methemoglobinemia induced by rasburicase in a pediatric patient: a case report and literature review., J Oncol Pharm Pract
Vadhan-Raj S et al., 2012, A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome., Ann Oncol
Youngster I et al., 2010, Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review., Drug Saf
Bain BJ, 2010, A ghostly presence-G6PD deficiency., Am J Hematol
Ducros J et al., 1991, Hemolytic anemia due to G6PD deficiency and urate oxidase in a kidney-transplant patient., Clin Nephrol
Joly P et al., 2009, [A severe G6PD deficiency revealed during a chemotherapy protocol including rasburicase]., Ann Biol Clin (Paris)
Bhat P et al., 2008, Exchange transfusion as treatment for rasburicase induced methemoglobinemia in a glucose-6-phosphate dehydrogenase deficient patient., Pediatr Blood Cancer
Borinstein SC et al., 2008, Methemoglobinemia and hemolytic anemia caused by rasburicase administration in a newly diagnosed child with Burkitt lymphoma/leukemia., Pediatr Blood Cancer
Browning LA et al., 2005, Hemolysis and methemoglobinemia secondary to rasburicase administration., Ann Pharmacother
Bosly A et al., 2003, Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study., Cancer
Patte C et al., 2002, Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Française d'Oncologie Pédiatrique LMB89 protocol., Ann Oncol

RASBURICASE G6PD

Interaction Score: 4.88

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9369411 29290749 28370399 27119769 26033222 25988058 25115783 24915143 24787449 24750455 24372186 23989394 23860572 23209099 22573495 22190578 22015451 20701405 20196170 2019023 19654083 18561168 17387701 16204390 12942574 12075750

Sources:
PharmGKB FDA
RASBURICASE CYB5R2

Interaction Score: 4.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RASBURICASE CYB5R4

Interaction Score: 4.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RASBURICASE CYB5R1

Interaction Score: 4.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RASBURICASE CYB5R3

Interaction Score: 1.55

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB

PharmGKB: rasburicase

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Borinstein SC et al., 2008, Methemoglobinemia and hemolytic anemia caused by rasburicase administration in a newly diagnosed child with Burkitt lymphoma/leukemia., Pediatr Blood Cancer

Pansy J et al., 2014, Cyanosis in a male Nigerian infant with acute kidney injury: answers., Pediatr Nephrol

Bain BJ, 2010, A ghostly presence-G6PD deficiency., Am J Hematol

ChemblDrugs: chembl:CHEMBL1201594
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
FDA: Rasburicase
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

RASBURICASE Drug Record

RASBURICASE chembl:CHEMBL1201594 Approved

Alternate Names:

Drug Info:

Publications:

RASBURICASE G6PD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9369411 29290749 28370399 27119769 26033222 25988058 25115783 24915143 24787449 24750455 24372186 23989394 23860572 23209099 22573495 22190578 22015451 20701405 20196170 2019023 19654083 18561168 17387701 16204390 12942574 12075750

Sources: PharmGKB FDA

RASBURICASE CYB5R2

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

RASBURICASE CYB5R4

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

RASBURICASE CYB5R1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

RASBURICASE CYB5R3

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

PharmGKB: rasburicase

Alternate Names:

Drug Info:

ChemblDrugs: chembl:CHEMBL1201594

Alternate Names:

Drug Info:

Publications:

FDA: Rasburicase

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
9369411 29290749 28370399 27119769 26033222 25988058 25115783 24915143 24787449 24750455 24372186 23989394 23860572 23209099 22573495 22190578 22015451 20701405 20196170 2019023 19654083 18561168 17387701 16204390 12942574 12075750

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB